I am a healthcare professional


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.


For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

ICML 2023

Coming soon
05:10 PM
Duration 15mins Auditorium, West USI Campus
Circulating tumor DNA (ctDNA) status and clinical outcomes in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study
Herrera AF, Tracy S, Sehn LH, Jardin F, Lenz G, Trněný M, Salles G, Flowers CR, Tilly H, Sharman JP, Friedberg JW, Balasubramanian S, Raghavan V, Hirata J, Lee C, Jiang Y, Morschhauser F
05:40 PM
Duration 15mins Cinema Corso
SUNMO: Phase III trial of mosunetuzumab plus polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in relapsed/refractory aggressive non-Hodgkin lymphoma
Pavlovsky A, Westin J, Olszewski AJ, Fogliatto L, Kim WS, Shin H-J, Leao D, Jeon Y-W, Norasetthada L, Rego E, Wu H, Yin S, Batlevi CL, Pham S, Penuel E, Jing J, Wei MC, Budde LE
02:15 PM
03:00 PM
Duration 15mins Room A, Palazzo dei Congressi
Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter’s transformation
Carlo-Stella C, Hutchings M, Offner F, Mulvihill E, Relf J, Byrne B, Lundberg L, Dickinson M
05:00 PM
Duration 15mins Polivalente Room, East USI Campus
Immune contexture analysis in POLARIX suggests response to Pola-R-CHP treatment reduces tumor microenvironment dependency
Morschhauser F, Hatzi K, Lenz G, Herrera AF, Flowers CR, Trněný M, Burke J, Hou JZ, Staber PB, Hawkes EA, Izutsu K, Le Gouill S, Belada D, Tucci A, Yan M, Harris W, Hirata J, Lee C, Jiang Y, Jardin F
04:30 PM
Duration 15mins Room A, Palazzo dei Congressi
Mosunetuzumab demonstrates durable responses in patients with relapsed and/or refractory follicular lymphoma and ≥2 prior therapies: updated analysis of a pivotal Phase II study
Sehn LH, Bartlett NL, Matasar M, Schuster SJ, Assouline S, Kuruvilla J, Shadman M, Cheah CY, Fay K, Ku M, Nastoupil L, Wei MC, Yin S, To I, Hu N, Min J, Penuel E, Belousov A, Coimbra A, Jemaa S, Bender B, Turner D, Budde LE
08:45 AM
Duration 15mins Room B, Palazzo dei Congressi
Glofitamab plus polatuzumab vedotin demonstrates durable responses and a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma
Hutchings M, Avigdor A, Sureda A, Terol MJ, Bosch F, Corradini P, Larsen TS, Dominguez AR, Skarbnik A, Joergenson J, Goldschmidt N, Gurion R, Zinzani PL, Pinto A, Cordoba R, Bottos A, Huang Z, Simko S, Relf J, Filézac de L’Etang A, Sellam G, Gritti G
09:30 AM
Duration 15mins Room B, Palazzo dei Congressi
Glofitamab monotherapy in patients with relapsed/refractory large B-cell lymphoma: extended follow-up and landmark analyses from a pivotal Phase II study
Dickinson M, Carlo-Stella C, Morschhauser F, Falchi L, Bachy E, Cartron G, Khan C, Tani M, Martinez-Lopez J, Bartlett N, Salar A, Brody J, Leppä S, Mulvihill E, Lundberg L, Relf J, Xie Y, Bottos A, Humphrey K, Hutchings M
10:00 AM
Duration 15mins Room A, Palazzo dei Congressi
Combining CD19-4-1BBL (RO7227166) with glofitamab is safe and shows early efficacy in patients suffering from relapsed or refractory B-cell Non-Hodgkin Lymphoma
M Dickinson, M Hutchings, C Carlo-Stella, F Morschhauser, F Bosch, G Gritti, W Townsend, NL Bartlett, G Cartron, H Ghesquieres, R Houot, H Walter, F Offner, A Christiansen, N Dimier, C Jamois, E Harrop, S Herter, G Hölzlwimmer, A Keelara, K Korfi, J Luong, C Mueller, S Mycroft, M Whayman, I Prieto, D Rukina, K Lechner
10:55 AM
Duration 15mins Room B, Palazzo dei Congressi
MURANO: Final 7 year follow up and retreatment analysis in venetoclax-rituximab (VenR)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)
Kater AP, Harrup R, Kipps TJ, Eichhorst B, Owen CJ, Assouline S, Lamanna N, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Mellink C, Chyla B, Thadani-Mulero M, Lefebure M, Jiang Y, Millen R, Boyer M, Seymour JF